
FDA Approves New Antibody-Drug Conjugate for Advanced Lung Cancer
On May 14, the Food and Drug Administration (FDA) granted accelerated approved of Emrelis (telisotuzumab vedotin) for certain people with advanced or metastatic lung cancer based on a study showing an overall response rate of 35%. Emrelis, from AbbVie, is …